about
Treatment of neuroendocrine tumors: new recommendations based on the CLARINET studyFrom targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsDosage and costs of lanreotide Autogel 120 mg administered as part of routine acromegaly care in Poland - two years of data from Lanro-Study.Well-differentiated gastric tumors/carcinomas.[Diagnostic and therapeutic opportunities in neuroendocrine tumors of the gastroenteropancreatic system].LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis.Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapyPolypeptide growth factors in gastroenteropancreatic neuroendocrine tumours.ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.Poorly-differentiated endocrine carcinomas of midgut and hindgut origin.ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation.Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from the prospective 12-month phase of Lanro-Study.ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors.ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms.Transforming growth factor β1 (TGFβ1) in physiology and pathology.Gastroduodenal neuroendocrine neoplasms including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Neuroendocrine neoplasms of the small intestine and the appendix - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Colorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Acromegaly--a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports.Quantitative ultrasound of the heel and serum and urinary cortisol values in assessment of long-term corticotherapy side effects in female bronchial asthma patients.Polish Society of Endocrinology Position statement on endocrine disrupting chemicals (EDCs).Successful EUS-guided ethanol ablation of insulinoma, four-year follow-up. Case report and literature review.Colorectal neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Serum concentrations of leptin, adiponectin, and interleukin-6 in postmenopausal women with Hashimoto's thyroiditis.Diagnostics and Treatment of Thyroid Carcinoma.Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours).Growth hormone/insulin-like growth factor-1 axis, calciotropic hormones and bone mineral density in young patients with chronic viral hepatitis.Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotideENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors.Melatonin, the RANKL/RANK/OPG system, and bone metabolism in girls with anorexia nervosa.Assessment of the relationship between circadian variations of salivary melatonin levels and type I collagen metabolism in postmenopausal obese women.Assessment of the relationship between dynamic pattern of nighttime levels of melatonin and chosen biochemical markers of bone metabolism in a rat model of postmenopausal osteoporosis.Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma melatonin and chosen hormones in breast cancer premenopausal patients.Influence of pinealectomy and long-term melatonin administration on GH-IGF-I axis function in male rats.Effects of hormone replacement therapy on endocrine and spirometric parameters in asthmatic postmenopausal women.Circadian serum levels of dehydroepiandrosterone sulphate in postmenopausal asthmatic women before and after long-term hormone replacement.Circadian rhythm of melatonin in postmenopausal asthmatic women with hormone replacement therapy.
P50
Q26770479-F5BCF992-FA81-4629-B5A1-0F57E04AF3DBQ26822011-82E9A223-A479-4C83-873A-6F3ADC14609EQ30941581-E8E0DB1C-63E4-4731-979A-7DFF27E94012Q34002549-A4BBE390-C48D-4D5A-A393-79561081111DQ34555911-49059B65-5D85-43F3-B5AE-679E617BC345Q35165592-BDAB81AD-411C-49DA-9EA8-0E4014597A95Q36437367-89DCD22A-4B03-4F1C-9C24-9125940303CBQ36758449-66D20719-3997-4A62-993F-1BCA9A5253D9Q36849357-69A6879F-F7E1-4DE4-8712-EEBFE5113179Q36972970-EF88231A-9F80-476D-B297-325AFBB5E0F1Q37588394-3B1FC9D4-D551-4E9F-93C6-2D1BD3BC0AEFQ37588397-96F0E019-E1E2-47DF-96C3-C8F4C730E97EQ37601860-5A0E2C72-08E3-4478-AE2B-DFD58ECD4CD2Q37756446-6102B8AD-ECCF-42DE-8DAE-123C2B66D816Q37977330-B77F00A0-307F-41CA-81C5-C2F80B3A7193Q38159543-9A8E01C8-B018-43B1-B1E4-6614389859D8Q38178902-29E7A105-DD2F-4FA9-96BD-6CEC73F58347Q38178903-D367783E-BF8D-40C8-84BB-B30E4CF22D2DQ38178905-A43E9BE7-DD3B-4A00-A86A-2DB4E1B5F261Q38178906-B892DD9B-2982-4D96-8E6D-2E33E4A6A3EBQ38245853-4AF1167B-DF7B-416A-A482-BCFD46C12B67Q38530265-7A33594E-9418-496D-A396-06A4F3B8B1F1Q38542005-17CDDD95-0232-445C-9390-E537ECCA9D4BQ38618789-4B9CC508-C419-4946-9199-99FC73F102AEQ38765743-5405F352-F63A-431E-8702-32889404B91EQ38765746-017189E3-F3B1-422F-A093-2093BBF4CCD9Q39894771-9BD16916-CD10-4B0A-BE7F-42A6ABB65454Q39992127-5A8EA99E-078D-4C90-8B79-A1369E258F2FQ40186992-47E4F2A0-1A0A-40FB-BD91-8D1972D2F77FQ41261068-464767B8-3AA8-4589-96A1-19F18785F4A0Q41691693-044B7A8A-9981-443C-BFAA-27D8456CBCF2Q42375203-CC06BB2C-3F27-40EB-9CEF-48EC93D9FF85Q43142034-793474DB-A1BC-4C78-813D-DD70351250E3Q43596772-BB86E222-8E94-4932-9EF1-EE180D8A41D1Q43596775-A2793852-5C24-49E7-B27F-4CF79A8DAA90Q43700109-977E5D8F-C870-4E27-B206-9A1CF4B52428Q43721408-7DEFF0DD-E334-44B5-BAD7-599B8C5226C8Q43739740-25B14CF8-5133-45BD-A94B-C9D850120CB4Q43891461-D5AB785E-9AD4-427A-A3DA-5006BA0B8F37Q44038882-1D8E25B9-C410-4952-AA3A-8C8C6C05827B
P50
description
Polish endocrinologist
@en
Pools onderzoekster
@nl
inchríneolaí Polannach
@ga
polska lekarka, endokrynolog
@pl
name
B Kos-Kudla
@ast
B Kos-Kudla
@nl
Beata Kos-Kudła
@ca
Beata Kos-Kudła
@cs
Beata Kos-Kudła
@en
Beata Kos-Kudła
@es
Beata Kos-Kudła
@ga
Beata Kos-Kudła
@gl
Beata Kos-Kudła
@hr
Beata Kos-Kudła
@hsb
type
label
B Kos-Kudla
@ast
B Kos-Kudla
@nl
Beata Kos-Kudła
@ca
Beata Kos-Kudła
@cs
Beata Kos-Kudła
@en
Beata Kos-Kudła
@es
Beata Kos-Kudła
@ga
Beata Kos-Kudła
@gl
Beata Kos-Kudła
@hr
Beata Kos-Kudła
@hsb
altLabel
B Kos-Kudla
@en
prefLabel
B Kos-Kudla
@ast
B Kos-Kudla
@nl
Beata Kos-Kudła
@ca
Beata Kos-Kudła
@cs
Beata Kos-Kudła
@en
Beata Kos-Kudła
@es
Beata Kos-Kudła
@ga
Beata Kos-Kudła
@gl
Beata Kos-Kudła
@hr
Beata Kos-Kudła
@hsb
P214
P1053
U-5389-2017
P106
P1412
P1559
Beata Kos-Kudła
@pl
P21
P214
P27
P31
P3124
P3829
P496
0000-0003-3755-1722
P735
P7859
viaf-250257121